Morf Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF healthcare integration platform ('Segment + Zapier for healthcare') syncing patient data across clinical tools for 10K+ patients; YC S22 $3.5M Kindred Ventures-backed serving mental health and chronic care tech-enabled providers.
About
Morf Health is a San Francisco-based healthcare data integration and workflow automation platform — backed by Y Combinator (S22) with $3.5 million raised including a $3 million seed round led by Kindred Ventures in November 2023, with participation from Uncommon Ventures and Asymmetric Capital — providing tech-enabled healthcare providers (virtual mental health practices, nutrition programs, chronic disease management companies, and preventive care platforms) with an integration and automation layer that synchronizes patient data across their clinical and operational tools stack, described as 'Segment plus Zapier for healthcare.' Founded in 2022 and having onboarded 10,000+ patients through integrated workflows, Morf addresses the data fragmentation problem that plagues digital health companies operating across 5-15 specialized clinical tools that don't natively integrate.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.